PennyOmega.com Hot Stock News & Alerts!
________________________________________
FREE Daily Stock Alerts From PennyOmega.com
________________________________________
Wednesday March 10, 2010
PennyOmega.com Stock Report!
**************************************************************
PWRM, Power 3 Medical Products Inc., PWRM.OB
PWRM is a leader in bio-medical research and the commercialization of neurodegenerative disease and cancer biomarkers, pathways, and mechanisms of diseases through the development of diagnostic tests and drug targets. PWRM’s patent-pending technologies are being used to develop screening and diagnostic tests for the early detection and prognosis of disease, identify protein biomarkers, and drug targets, and its diagnostic tests are targeted toward markets with critical unmet needs in areas including neurodegenerative disease (NuroPro) and breast cancer (BC-SeraPro). PWRM operates a state-of-the-art CLIA certified laboratory in The Woodlands (Houston), Texas and continues to evolve and enhance its IP portfolio, employing sensitive and specific combinations of biomarkers it has discovered from a broad range of diseases as the basis of highly selective blood-based tests for ALS, Alzheimer’s, and Parkinson’s diseases, breast cancer, and drug resistance.
** PWRM reported that 4 abstracts covering results from clinical validation trials of the NuroPro(R) AD test for Alzheimer’s disease were submitted to the 2010 annual meeting of the International Congress of Alzheimer’s Disease, taking place July 2010. The NuroPro AD test was developed to help clinicians distinguish patients with Alzheimer’s disease from “normal” individuals and patients with other neurological disorders. The test, developed by PWRM, is a panel of 57 blood serum protein biomarkers evaluated by biostatistical analysis to predict the probability a patient has Alzheimer’s disease. The test is intended to solve the critical challenge facing physicians, clinicians, and patients for quick, early stage, and accurate diagnosis of this debilitating disease as well as to provide guidance for therapy, and monitor treatment response.
The four studies present the capabilities of NuroPro for accurate diagnosis, targeted therapy and drug response monitoring. They involve a total of 154 Alzheimer’s disease and 91 Parkinson’s disease patients, 210 age-matched normal and 173 disease control individuals. The abstracts report the combined results from the clinical validation trials of the NuroPro(R) AD and NuroPro PD tests, conducted by the PWRM scientific team, led by medical director Lourdes R. Bosquez, MD and chief scientific officer, Ira L. Goldknopf, Ph.D., in collaboration with Marwan Sabbagh, MD, director of the Banner Sun Health Research Institute, Sun City, Arizona, Katerina Markopoulou, M.D., Assistant Professor of Neurology at the University of Thessaly, Larissa Greece, along with previous studies PWRM conducted with Stanley H. Appel, MD during his tenure as Chairman of Neurology, Baylor College of Medicine, Houston TX. Dr. Appel is now Co-Director of the Methodist Neurological Research Institute, Houston, TX, and continues to be chairman of the scientific advisory board of Power3.
Furthermore, PWRM has signed a definitive agreement to acquire all of the stock of StemTroniX Inc. PWRM plans to effectuate the acquisition of StemTroniX by merging a wholly owned subsidiary of the Company with and into StemTroniX. StemTroniX will remain as the surviving company in the merger and will become a wholly owned subsidiary of PWRM. The acquisition of StemTroniX is expected to be completed in April 2010.
More about PWRM at www.Power3Medical.com
**************************************************************
ABT, Abbott Laboratories
ABT is a global, broad-based health care company devoted to the discovery, development, manufacture and marketing of pharmaceuticals and medical products, including nutritionals, devices and diagnostics.
ABT has received U.S. Food and Drug Administration (FDA) approval for the TECNIS(R) Multifocal 1-Piece intraocular lens (IOL) for cataract patients with and without presbyopia.
Intraocular lenses are implanted in a patient’s eye after the removal of the natural lens that has become clouded by a cataract. Conventional monofocal IOLs are designed to focus primarily at one distance and do not correct presbyopia, an age-related change in vision that occurs when the eye’s natural lens can no longer adjust its focal length to allow clear vision at different distances.
The TECNIS lens has also received presbyopia-correcting IOL status by the Centers for Medicare and Medicaid Services (CMS), providing Medicare beneficiaries with the option to receive a TECNIS Multifocal 1-Piece lens for an additional fee as part of cataract surgery.
The TECNIS Multifocal 1-Piece IOL is a pupil-independent, full diffractive presbyopia-correcting lens designed for optimal image quality at all distances under any lighting condition. Its unique optic design gives patients superior near vision and reading speed compared to other presbyopia-correcting IOLs.
TECNIS multifocal IOLs are indicated for primary implantation for the visual correction of adult patients with and without presbyopia in whom a cataractous lens has been removed and who desire near, intermediate, and distance vision with increased spectacle independence. The intraocular lenses are intended to be placed in the capsular bag. Abbott has begun shipping TECNIS Multifocal 1-Piece IOLs in select markets and plans for full commercial shipments to begin in April 2010.
More about ABT at www.abbottmedicaloptics.com.
**************************************************************
***********Advertisement***********
.png)
.png)
.png)
********************************
Disclaimer: Our disclaimer is to be read and fully understood before using our site, reading our newsletter or joining our email list. Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment (read more ) Rule 17B requires disclosure of payment for investor relations. Crown Equity Holdings, Inc. (CRWE.OB) has previously received five hundred thousand shares compensation for 30 days of advertisement services and it has received an additional 1,000,000 shares 144 restricted stocks for 6 months of advertisement and diseminate news and $15,000 dollars for IR services for Power 3 Medical Products Inc. (PWRM.OB).
